Comparative Acute Effects of LSD, Psilocybin and Mescaline (NCT04227756) | Clinical Trial Compass
CompletedPhase 1
Comparative Acute Effects of LSD, Psilocybin and Mescaline
Switzerland32 participantsStarted 2020-05-19
Plain-language summary
LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. However, there are differences in the substances' molecular structures and receptor activation profiles which may induce differential subjective effects. To date, there are no modern studies comparing LSD, psilocybin and mescaline directly within the same clinical study and research subjects using validated psychometric tools. Therefore, the LPM-Study compares the acute effects of LSD, psilocybin, mescaline and placebo in a double-blind, placebo-controlled, 4-period cross-over design with four treatment conditions: 1) 100 μg LSD, 2) 20 mg psilocybin, 3) 300 or 500 mg mescaline, and 4) placebo.
Who can participate
Age range25 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 25 and 65 years old
✓. Sufficient understanding of the German language
✓. Understanding of procedures and risks associated with the study
✓. Willing to adhere to the protocol and signing of the consent form
✓. Willing to refrain from the consumption of illicit psychoactive substances during the study
✓. Abstaining from xanthine-based liquids from the evenings prior to the study sessions to the end of the study days
✓. Willing not to operate heavy machinery within 48 hours after substance administration
✓. Willing to use double-barrier birth control throughout study participation
Exclusion criteria
✕. Chronic or acute medical condition
✕. Current or previous major psychiatric disorder
What they're measuring
1
5 Dimensions of Altered States of Consciousness (5D-ASC)